Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

BETHESDA, Md., April 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.

MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers. Additionally, EpCAM has been found on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers. MT110 is the second BiTE antibody in clinical trials, and the fourth clinical program in Micromet's product pipeline. The first BiTE antibody, MT103 (MEDI-538), is now in phase 1 and phase 2 clinical trials for the treatment of haematological cancers.

"BiTE antibodies enable the patients' own T cells to very efficiently eliminate tumor cells," comments Patrick Baeuerle, Chief Scientific Officer of Micromet, "In various experimental tumor models, we have demonstrated the high therapeutic potential of EpCAM-specific BiTE antibodies, and we are now looking forward to determining the safety and the therapeutic potential of MT110 in patients."

"Having obtained clinical proof of concept for our BiTE antibody technology with MT103 in haematological cancers, we are excited about exploring the potential of MT110 in treating solid tumors," comments Carsten Reinhardt, Chief Medical Officer of Micromet. "Based on its unique mode of action, MT110 may be suited to treat established tumors as well as disseminated cancer cells, which frequently give rise to metastases."

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung and gastrointestinal cancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.

About Micromet, Inc. (

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung and gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "suggests," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
(Date:11/24/2015)... -- The uptake of recently approved and pipeline premium products ... market growth to 2021, says GBI Research . ... for Type 1 Diabetes Mellitus (T1DM), will be a key driver of ... --> The uptake of recently approved and pipeline premium ... of market growth to 2021, says GBI Research ...
(Date:11/24/2015)... 24, 2015   Renowned ... deliver s advice and insights on ... More than 50% of Dubai ... according to the DHA   femMED launches comprehensive solutions for ... Dubai residents are not consuming enough to keep ...
(Date:11/24/2015)...  Freudenberg Medical has developed specialty tubing for an inexpensive, ... facilities. Africa and ... Nevertheless, prompt diagnosis is important to treat those affected and ... the help of a portable mini-lab or "lab on a ... affected areas and perform rapid testing for HIV. They do ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... announces Fragrance by Marcelle, a cosmetic invention which offers a combination of natural ... Market in the US is worth $3 billion annually," says Scott Cooper, CEO ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the Business Action on Health Awards, bestowed annually to the world’s best corporate-supported ... commended companies at Global Health Council’s Landscape Symposium held in Washington D.C and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The OSHA Training ... Institute Education Center in Northern California, is calling on retail employers to implement ... As the volume of sales and shoppers rapidly expands, retailers are strongly ...
(Date:11/24/2015)... ... 24, 2015 , ... There’s nothing better than giving the gift of green ... enjoy. , This year, gardens are popping up in the most unexpected places. ... , Vita Gardens’ African Keyhole Garden Bed ($499) , Water conscious gardeners – and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Wireless Analytics, ... today announced new 24-hour weekday support capability. The “all hours” offering was ... Analytics’ international customers, and to enhance after-hours support available in the US. , ...
Breaking Medicine News(10 mins):